One of the world’s leading causes of death is cancer and one million new cancer cases are identified, and millions of people die every year from this deadly disease. The small silver lining of the whole sad problem is that if cancer is diagnosed in time, millions of individuals will… Read more
Solid Tumors

Solid tumors, as the name suggests, are solid masses devoid of fluids or cysts. Tumors that are solid may be either malignant or benign. Solid tumors may only have a different appearance than blood tumors but can also need a different treatment procedure. In the muscles, bone, and organs of the body, solid tumors may develop. Mesothelioma, sarcomas, lymphomas, sarcomas and cancers of the breast, prostate, kidney, ovary, pancreas, thyroid, and colon are examples. Solid tumors are categorized using grades based on the anomalies found in tumor cells by pathologists and how likely the tumor is to spread.

Breast Cancer

The risk of breast cancer may be increased by mutations in the BRCA1 and BRCA2 (breast cancer 1 and breast cancer 2) genes. BRCA mutations can be inherited, and an increased risk of developing cancer is associated with them. For individuals with a personal or family history of cancer, or for those with a particular form of breast cancer, the BRCA gene test is usually prescribed. Usually, the procedure is not carried out on people with an average risk of breast cancer.

BRCA 1 & BRCA 2 Mutation Analysis 

BRCA1 & BRCA2 germline mutations cause inherited breast syndrome and account for about 5-10 % of all cases of breast cancer, and 90% of breast cancer in the family. Mutations impart increased early risk breast cancer, multiple primary breast cancer, male breast cancer, epithelial ovarian cancer, fallopian cancer. Mutations of the BRCA2 are also related to an increased risk of melanoma. In triple-negative breast cancer, the prevalence of the BRCA mutation is increased, especially among younger patients. Mutation prevalence is in the general population, about 1/300 for BRCA1 and 1/800 for BRCA2, with some groups with a higher incidence due to mutations of the founders.  Genetic testing promotes therapy selection, preparation for monitoring, and identification of family members at risk. 

This test is carried out by sequencing the entire genes of BRCA1 and BRCA2 using massive parallel sequencing, point mutation detection methodologies, small & large insertions / deletions and copy number variations.

Comprehensive Cancer Panel

The exons of 409 tumour suppressor genes and oncogenes commonly cited and frequently mutated are targeted by the Comprehensive Cancer Panel. Strategically designed to simultaneously analyse coding DNA sequences and splice variants across multiple gene families, our pathway-based gene selection processes the mutational continuum, along with signalling cascades, in cancer driver genes and drug targets. In a single assay, apoptosis genes, DNA repair genes, transcription regulators, genes for inflammatory response and growth factor genes.

Advantages

  • Wide survey of 409 primary genes in a simple reaction.
  • Unmatched plexy with our technology of 16,000 primer pairs in four pools only.
  • Low DNA input of only 40 ng DNA and short amplicons make FFPE samples and biopsies of needles.
  • Rapidly launch detailed genomic studies with pre-designed primer pools.
  • Simplify variant analysis and annotation with tools.

Comprehensive Cancer Panel target gene list

 

ABL1 AURKC BTK CEBPA DDR2 ERG FLT1 HLF
ABL2 AXL BUB1B CHEK1 DEK ESR1 FLT3 HNF1A
ACVR2A BAI3 CARD11 CHEK2 DICER1 ETS1 FLT4 HOOK3
ADAMTS20 BAP1 CASC5 CIC DNMT3A ETV1 FN1 HRAS
AFF1 BCL10 CBL CKS1B DPYD ETV4 FOXL2 HSP90AA1
AFF3 BCL11A CCND1 CMPK1 DST EXT1 FOXO1 HSP90AB1
AKAP9 BCL11B CCND2 COL1A1 EGFR EXT2 FOXO3 ICK
AKT1 BCL2 CCNE1 CRBN EML4 EZH2 FOXP1 IDH1
AKT2 BCL2L1 CD79A CREB1 EP300 FAM123B FOXP4 IDH2
AKT3 BCL2L2 CD79B CREBBP EP400 FANCA FZR1 IGF1R
ALK BCL3 CDC73 CRKL EPHA3 FANCC G6PD IGF2
APC BCL6 CDH1 CRTC1 EPHA7 FANCD2 GATA1 IGF2R
AR BCL9 CDH11 CSF1R EPHB1 FANCF GATA2 IKBKB
ARID1A BCR CDH2 CSMD3 EPHB4 FANCG GATA3 IKBKE
ARID2 BIRC2 CDH20 CTNNA1 EPHB6 FAS GDNF IKZF1
ARNT BIRC3 CDH5 CTNNB1 ERBB2 FBXW7 GNA11 IL2
ASXL1 BIRC5 CDK12 CYLD ERBB3 FGFR1 GNAQ IL21R
ATF1 BLM CDK4 CYP2C19 ERBB4 FGFR2 GNAS IL6ST
ATM BLNK CDK6 CYP2D6 ERCC1 FGFR3 GPR124 IL7R
ATR BMPR1A CDK8 DAXX ERCC2 FGFR4 GRM8 ING4
ATRX BRAF CDKN2A DCC ERCC3 FH GUCY1A2 IRF4
AURKA BRD3 CDKN2B DDB2 ERCC4 FLCN HCAR1 IRS2
AURKB BRIP1 CDKN2C DDIT3 ERCC5 FLI1 HIF1A ITGA10
ITGA9 MALT1 MTR NTRK1 PKHD1 RNASEL SSX1 TPR
ITGB2 MAML2 MTRR NTRK3 PLAG1 RNF2 STK11 TRIM24
ITGB3 MAP2K1 MUC1 NUMA1 PLCG1 RNF213 STK36 TRIM33
JAK1 MAP2K2 MUTYH NUP214 PLEKHG5 ROS1 SUFU TRIP11
JAK2 MAP2K4 MYB NUP98 PML RPS6KA2 SYK TRRAP
JAK3 MAP3K7 MYC PAK3 PMS1 RRM1 SYNE1 TSC1
JUN MAPK1 MYCL1 PALB2 PMS2 RUNX1 TAF1 TSC2
KAT6A MAPK8 MYCN PARP1 POU5F1 RUNX1T1 TAF1L TSHR
KAT6B MARK1 MYD88 PAX3 PPARG SAMD9 TAL1 UBR5
KDM5C MARK4 MYH11 PAX5 PPP2R1A SBDS TBX22 UGT1A1
KDM6A MBD1 MYH9 PAX7 PRDM1 SDHA TCF12 USP9X
KDR MCL1 NBN PAX8 PRKAR1A SDHB TCF3 VHL
KEAP1 MDM2 NCOA1 PBRM1 PRKDC SDHC TCF7L1 WAS
KIT MDM4 NCOA2 PBX1 PSIP1 SDHD TCF7L2 WHSC1
KLF6 MEN1 NCOA4 PDE4DIP PTCH1 Sep-09 TCL1A WRN
KRAS MET NF1 PDGFB PTEN SETD2 TET1 WT1
LAMP1 MITF NF2 PDGFRA PTGS2 SF3B1 TET2 XPA
LCK MLH1 NFE2L2 PDGFRB PTPN11 SGK1 TFE3 XPC
LIFR MLL NFKB1 PER1 PTPRD SH2D1A TGFBR2 XPO1
LPHN3 MLL2 NFKB2 PGAP3 PTPRT SMAD2 TGM7 XRCC2
POT1 MLL3 NIN PHOX2B RAD50 SMAD4 THBS1 ZNF384
LPP MLLT10 NKX2-1 PIK3C2B RAF1 SMARCA4 TIMP3 ZNF521
LRP1B MMP2 NLRP1 PIK3CA RALGDS SMARCB1 TLR4  
LTF MN1 NOTCH1 PIK3CB RARA SMO TLX1
LTK MPL NOTCH2 PIK3CD RB1 SMUG1 TNFAIP3
MAF MRE11A NOTCH4 PIK3CG RECQL4 SOCS1 TNFRSF14
MAFB MSH2 NPM1 PIK3R1 REL SOX11 TNK2
MAGEA1 MSH6 NRAS PIK3R2 RET SOX2 TOP1
MAGI1 MTOR NSD1 PIM1 RHOH SRC TP53

 

RNA fusion panel for Lung Cancer

The most prevalent cancer worldwide is lung cancer. In 2012, there were some 1.82 million new cases worldwide and 1.56 million deaths, representing about 20 percent of all cancers. In India, 6.9% of all new cases of cancer and 9.3% of all cancer-related deaths in both sexes are lung cancer, the most common cancer and cause of cancer-related mortality in men, with the highest recorded incidences.

Chromosome aberrations have been shown to play an important role in the initial steps of tumorigenesis, especially translocations and their subsequent gene fusions. The identification of gene fusions indicates the hope that personalized cancer care decisions will play an important role in the future. In fresh-frozen solid tumours from common cancers, through next-generation sequencing technology, several uncommon gene fusion events have been identified.

This research panel targets over 70 fusion transcripts and has a sensitivity of 1% and the key advantage over current technologies (namely multi-colour fluorescent in situ hybridization (FISH) and array comparative genomic hybridization (array CGH) is the simplicity of the technique and its associated labour savings, with only a 10ng input RNA requirement and five housekeeping genes as an internal quality control.

RNA fusion panel targeted gene list

KRAS EGFR BRAF PIK3CA AKT1 ERBB2
PTEN NRAS STK11 MAP2K1 ALK DDR2
CTNNB1 MET TP53 SMAD4 FBX7 FGFR3
NOTCH1 ERBB4 FGFR1 FGFR2    

Get in touch